Current Beat
Jun | 24 | 2026
Press Release
Passage Bio and Remix Therapeutics™ Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers Concurrent oversubscribed $100 million private placement […]
Mar | 19 | 2026
Press Release
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor Adenoid Cystic Carcinoma WATERTOWN, Mass., March 19, 2026 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing […]
May | 19 | 2025
News
REMastering Drug Discovery: Harnessing RNA Processing to Tackle 'Undruggable' Proteins
My dad passed away when he was just fifty-six from acute myeloid leukemia (AML). Even with all the progress we’ve made treating cancer, it’s one of those diseases that still leaves too many people and families with too few options. The outlook can be particularly tough depending on factors like age, other health issues, and […]
It's Sound Science
